Cel-Sci stock analysis
Cel-Sci (LSR) Stock Price & Analysis
LSR Stock Chart & Stats
- Day’s Range
- EUR 1.15 - EUR 1.54
- 52-Week Range
- EUR 0.76 - EUR 6.35
- Previous Close
- EUR 1.17
- Volume
- N/A
- Average Volume (3M)
- 108
- Market Cap
- EUR 20.43M
- Enterprise Value
- EUR 13.97M
- Total Cash (Recent Filing)
- EUR 6.53M
- Total Debt (Recent Filing)
- EUR 7.89M
- Price to Earnings (P/E)
- ―
- Beta
- 1.97
- Next Earnings
- Dec 23, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Immunotherapy Focus
CEL-SCI has a focused biotechnology strategy centered on immune-system modulation, with Multikine as its core development program. If clinical development succeeds, this specialized platform could support a differentiated position in cancer treatment and create long-term commercial opportunity.
CDMO Operations
The CDMO segment provides an operating capability beyond the internal drug pipeline and gives the company experience in biologics development and manufacturing. This diversification could support strategic relevance and potentially broaden future revenue sources if the service business scales.
Historically Moderate Leverage
Historical leverage was generally moderate and shareholders’ equity remained positive, indicating that the company had not previously relied on excessive debt relative to its capital base. That balance-sheet profile can provide more flexibility than highly leveraged development-stage peers.
Bears Say
No Commercial Revenue
Zero reported revenue confirms that CEL-SCI has not yet demonstrated a commercial sales base. The business therefore remains dependent on successful development and commercialization of its programs, leaving revenue visibility, scalability, and operating self-sufficiency unproven.
Persistent Losses And Cash Burn
Consistently negative operating and free cash flow means the company is not currently self-funding its operations. Continued losses and annual cash burn can require additional financing over time, potentially limiting strategic flexibility and increasing dependence on capital markets.
Balance-Sheet Volatility
The sharp TTM increase in reported debt and the accompanying expansion in assets and equity represent a major departure from historical levels. This discontinuity raises uncertainty around balance-sheet stability and makes future leverage, capital efficiency, and financial risk harder to assess.
Cel-Sci News
LSR FAQ
What was Cel-Sci’s price range in the past 12 months?
What is Cel-Sci’s market cap?
When is Cel-Sci’s upcoming earnings report date?
How were Cel-Sci’s earnings last quarter?
Is Cel-Sci overvalued?
Does Cel-Sci pay dividends?
What is Cel-Sci’s EPS estimate?
How many shares outstanding does Cel-Sci have?
What happened to Cel-Sci’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cel-Sci?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Cel-Sci
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Geert R. Kersten
- Employees
- 43
- Website
- cel-sci.com
- Address
- 8229 Boone Boulevard, Vienna, VA, 22182, US
Cel-Sci (LSR) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 4 | 12 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 2 | 0 | 10 |









